Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: VYLIBRA — Supplemental Application (Afaxys Pharma, LLC)

View source ↗

Summary

FDA approved a supplemental application for VYLIBRA (norgestimate and ethinyl estradiol) from Afaxys Pharma, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VYLIBRA (Norgestimate and Ethinyl Estradiol)

Snippet

SUPPL AP for VYLIBRA (NORGESTIMATE AND ETHINYL ESTRADIOL)